Pharmafile Logo

News and Press Releases

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 6, 2025

Abivax
info@abivax.com
7-11 Boulevard Haussmann 75009 Paris

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2025

argenx
ukmediainfo@argenx.com
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG

Northern Gritstone invests in Manchester spinout Apini

Northern Gritstone has committed £1.8 million to Apini, a spinout from the University of Manchester Apini is a novel small molecule therapeutic programme for the treatment of multiple chronic inflammatory...

Category: Biotechnology, Other, Pharmaceutical
Posted: June 11, 2025

Northern Gritstone
enquiries@northern-gritstone.com
No.1 Circle Square 3 Symphony Park Manchester M1 7FS

European Commission approves TREMFYA (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

TREMFYA (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remissiona and endoscopic responseb at Week 12 compared to placebo...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 7, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

TREMFYA (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 28 March 2025 -- Beerse, Belgium -- Johnson & Johnson today announced that...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 28, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis

Risankizumab will be available on the NHS in Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to,...

Category: Clinical Trials, Pharmaceutical
Posted: January 13, 2025

AbbVie
AbbVie House Vanwall Business Park Vanwall Road Maidenhead Berkshire SL6 4UB

Spur provides update on FLT201 and planned phase III clinical trial

8 July 2024 -- London, UK -- Syncona Ltd, a leading life science investor focused on creating, building and scaling global leaders in life science, notes that its portfolio company...

Category: Clinical Trials, Other, Pharmaceutical
Posted: July 8, 2024

Syncona
contact@synconaltd.com
2nd Floor, 8 Bloomsbury Street, London, WC1B 3SR

NICE Recommends Lilly’s Mirikizumab (OMVOH) for the Treatment of Eligible Adults with Moderately to Severely Active Ulcerative Colitis.

22 September 2023 -- Basingstoke, UK -- Eli Lilly and Company announced today that the National Institute for Health and Care Excellence (NICE) have recommended mirikizumab for the treatment of...

Category: Pharmaceutical
Posted: September 22, 2023

Eli Lilly
ukpublicaffairs@lilly.com
450 Kendall Street Cambridge, MA 02142